Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
PaperCitations, authors & open-access status
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 367 citations, 2020 year and hybrid oa status.
367
Citations
2020
Year
hybrid
OA Status